<DOC>
	<DOCNO>NCT00061984</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy doxorubicin ifosfamide use different way stop tumor cell divide stop grow die . Colony-stimulating factor , pegfilgrastim , cause body make blood cell . It yet know whether doxorubicin alone effective without ifosfamide pegfilgrastim treat soft tissue sarcoma . PURPOSE : This randomized phase III trial study give doxorubicin alone see well work compare give doxorubicin together ifosfamide pegfilgrastim treat patient locally advance metastatic soft tissue sarcoma .</brief_summary>
	<brief_title>Doxorubicin With Without Ifosfamide Pegfilgrastim Treating Patients With Locally Advanced Metastatic Soft Tissue Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare progression-free overall survival patient locally advance metastatic soft tissue sarcoma treat doxorubicin v without ifosfamide pegfilgrastim first-line therapy . - Compare response patient treat regimen . - Compare treatment-related mortality patient treat regimen . - Compare toxicity regimens patient . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord WHO performance status ( 0 vs 1 ) , age group ( less 50 year age vs 50 year age ) , presence liver metastasis ( yes v ) , histological grade ( 2 vs 3 ) , participate center . Patients randomize 1 2 treatment arm . - Arm I : Patients receive doxorubicin IV day 1 ( IV continuously day 1-3 ) . - Arm II : Patients receive doxorubicin IV day 1-3 ifosfamide IV 4 hour day 1-4 . Patients also receive pegfilgrastim subcutaneously day 5 . In arm , treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . Patients follow every 8 week disease progression every 12 week thereafter . PROJECTED ACCRUAL : A total 450 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm soft tissue sarcoma Locally advance unresectable* OR metastatic disease Highgrade ( grade 23 ) disease accord FNLCC grading system NOTE : *Disease could prove resectable ( include pulmonary metastasectomy ) response chemotherapy allow The following tumor type eligible : Malignant fibrous histiocytoma Myxoid round cell liposarcoma , pleomorphic liposarcoma , dedifferentiate liposarcoma Pleomorphic rhabdomyosarcoma Synovial sarcoma Myxofibrosarcoma , intermediate highgrade Fibrosarcoma Leiomyosarcoma Angiosarcoma Malignant peripheral nerve sheath tumor Epithelioid sarcoma Alveolar rhabdomyosarcoma Unclassifiable sarcoma , otherwise specify The following tumor type eligible : Gastrointestinal stromal tumor Mixed mesodermal tumor Chondrosarcoma Malignant mesothelioma Neuroblastoma Osteosarcoma Ewing 's sarcoma/primitive neuroectodermal tumor Desmoplastic small round cell tumor Embryonal rhabdomyosarcoma Alveolar soft part sarcoma Must measurable lesion clinical evidence progression within past 6 week Osseous lesion pleural effusion consider measurable No know symptomatic CNS metastases PATIENT CHARACTERISTICS : Age 18 60 Performance status WHO 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 1.8 mg/dL Albumin least 2.5 g/dL Renal Creatinine great 1.4 mg/dL OR Creatinine clearance great 65 mL/min Cardiovascular No history cardiovascular disease Other Not pregnant Negative pregnancy test Fertile patient must use effective contraception No severe medical illness No psychosis No prior concurrent malignancy except adequately treat carcinoma situ cervix basal cell skin cancer No psychological , familial , sociological , geographical condition would preclude study compliance followup schedule PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy advanced metastatic disease Prior adjuvant chemotherapy allow provided disease progression within 6 month completion treatment Endocrine therapy Not specify Radiotherapy No prior radiotherapy sole index lesion Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>adult angiosarcoma</keyword>
	<keyword>adult epithelioid sarcoma</keyword>
	<keyword>adult fibrosarcoma</keyword>
	<keyword>adult leiomyosarcoma</keyword>
	<keyword>adult liposarcoma</keyword>
	<keyword>adult rhabdomyosarcoma</keyword>
	<keyword>adult synovial sarcoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>adult malignant fibrous histiocytoma</keyword>
	<keyword>adult neurofibrosarcoma</keyword>
	<keyword>stage II adult soft tissue sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
</DOC>